Company Focus
Astellas Pharma
Latest Astellas Pharma News
Biotechnology
The US Food and Drug Administration has approved Vyloy (zolbetuximab-clzb), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine and platinum-containing chemotherapy, from Japanese drug major Astellas Pharma. 19 October 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Astellas Pharma
Pharmaceutical
Eli Lilly released positive top-line results from the SUMMIT Phase III clinical trial evaluating the safety and efficacy of tirzepatide injection in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. 1 August 2024
Biotechnology
US biotech Biogen reported its second-quarter financial results and published its latest guidance on Thursday. 1 August 2024
Biotechnology
mRNA specialist Moderna (Nasdaq: MRNA) has reported a decline in revenues for the second quarter, taking in $241 million, down from $344 million in the same period last year. 1 August 2024
Biosimilars
Chinese biotech Bio-Thera Solutions (SHSE: 688177) has picked up European Medicines Agency approval for BAT1706, a biosimilar referencing Avastin (bevacizumab). 1 August 2024
Biotechnology
IDEAYA Biosciences has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with Chinese biotech Biocytogen Pharmaceuticals. 1 August 2024
Biotechnology
Boston, USA-based vaccines company HilleVax has attempted to stem the tide following its announcement of disastrous norovirus trial results last month. 1 August 2024
Pharmaceutical
Merck KGaA (MRK: DE) has reported strong financial results for the second quarter of 2024, driven largely by its robust performance in its life sciences business. 1 August 2024
Generics
Shares in Israeli drugmaker Teva Pharmaceutical Industries closed 4% higher following Wednesday’s trading in Tel Aviv. 31 July 2024
Biotechnology
Chinese biotech company LTZ Therapeutics has announced the completion of its series A financing round, raising over $20 million. 31 July 2024
Pharmaceutical
Shares in UK pharma major GSK were 2% lower in London’s early afternoon trading on Wednesday. 31 July 2024
Latest In Brief for Astellas Pharma
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
13 November 2024
30 October 2024
28 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze